No Man's Sky's latest update gives us creatures we can train and fight against one another, like some kind of pocket monster ...

One of the best isekai anime series of all time is finally streaming on Netflix. Read on to find out more about it.

Mud at a back door is more than a nuisance on the doormat. It grinds into flooring, ruins baseboards and turns every rainy ...

Young American EV startup, Slate Auto, has shared its latest video update, and it’s a chilly one. The company’s development prototypes were recently put through extreme winter testing in Northern ...

Many are anxiously awaiting the arrival of the Slate Truck, the back-to-basics all-electric pickup (that can convert to an SUV) with backing from Jeff Bezos, but it’s been a while since we heard any ...

As fuel costs continue to rise, a budget-friendly electric vehicle might be on your radar. The Slate Truck is now taking reservations for orders — you can hold your spot in line for $50. The simple, ...

Slate Auto is becoming an example of what a small startup can do with vast amounts of cash. It’s navigated several trials and tribulations and market shifts that other, less well-funded EV startups ...

As most car companies follow the Tesla playbook by doubling down on giant touchscreens and flashy software, Slate is going in the complete opposite direction. The startup debuted its first vehicle on ...

Slate has hired former Amazon Marketplace vice president Peter Faricy as its new Chief Executive Officer. With Slate Auto nearing the debut of its all-electric vehicle, the startup has appointed Peter ...

Slate Auto, the electric vehicle startup backed by Jeff Bezos, has replaced its CEO months ahead of the launch of its affordable electric truck. Former Amazon Marketplace vice president Peter Faricy ...

Prefer Newsweek on Google to see more of our trusted coverage when you search. Peter Faricy today assumed the role of Chief Executive Officer of Slate Auto, an American electric vehicle startup.

Slate Medicines has emerged with hopes of cracking the code for delivering an injectable novel drug class to prevent migraines, an area where others—such as Eli Lilly and Amgen—have previously failed.